Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
You may also be interested in...
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
$5.1bn alliance is most eyecatching deal of the year – but is only a start for Gilead's rebuilding program.
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.